This study using bioinformatics methods to analyze the expression level and prognostic value of ferroptosis driver genes (FDGs) in clear cell renal cell cancer (ccRCC), and provide theoretical basis for the molecular regulatory mechanism and clinical application of FDGs in ccRCC. The Kidney Clear Cell Cancer dataset from the UCSC Xena database was selected, and differentially expressed genes (DEGs) were screened using R software. Functional enrichment analysis was performed on DEGs using the DAVID database. Filter the FDGs in DEGs based on the FDGs in the FerrDb database. Prognostic analysis was performed using Kaplan-Meier method with the survival information of ccRCC patients in UCSC Xena database. This study using TIMER2.0 database to analyze the expression level of FDGs in pan cancer. 252 DEGs were obtained through screening, mainly enriched in biological processes such as transmembrane transport of sodium/potassium/chloride ions, sodium potassium ion homeostasis, renal water homeostasis, and aldosterone regulated sodium reabsorption pathways. By intersecting with the FDGs, three genes were obtained: PVT1, HILPDA, and CDKN2A. They are upregulated in ccRCC tumor tissue. The analysis results of survival suggest that high expression of PVT1 and CDKN2A is relevant to poor prognosis in ccRCC patients. The analysis of pan cancer showed that PVT1 and CDKN2A were highly expressed in bladder cancer, breast cancer and other tumors. Patients of ccRCC with high expression level of PVT1 and CDKN2A have poor prognosis, and both have great importances in the formation and progression of ccRCC, which may become biomarkers for the prognosis of ccRCC.

Yinsong Hu, Haitao Jiao, Lei Liu, Jinyan Zhao. Analysis of Expression Level and Prognostic Value of Ferroptosis Driver Genes in Clear Cell Renal Cell Carcinoma. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 12: 29-34. https://doi.org/10.25236/IJFM.2024.061205.

[1] F. Bray, M. Laversanne, H. Sung, J. Ferlay, R. L. Siegel, I. Soerjomataram, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263

[2] P. Makhov, S. Joshi, P. Ghatalia, A. Kutikov, R. G. Uzzo, V. M. Kolenko. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther, 2018, 17(7): 1355-1364

[3] I. El-Mokadem, J. Fitzpatrick, J. Bondad, P. Rauchhaus, J. Cunningham, N. Pratt, et al. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery. Br J Cancer, 2014, 111(7): 1381-1390

[4] J. Li, F. Cao, H. L. Yin, Z. J. Huang, Z. T. Lin, N. Mao, et al. Ferroptosis: past, present and future. Cell Death Dis, 2020, 11(2): 88

[5] Y. Mou, J. Wang, J. Wu, D. He, C. Zhang, C. Duan, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol, 2019, 12(1): 34

[6] X. Jiang, B. R. Stockwell, M. Conrad. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282

[7] Y. Lu, H. Qin, B. Jiang, W. Lu, J. Hao, W. Cao, et al. KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma. Cancer Lett, 2021, 522: 1-13

[8] D. Yang, Z. He, J. Lu, X. Yuan, H. Liu, Y. Xue, et al. Downregulation of GDF15 suppresses ferroptosis and predicts unfavorable prognosis in clear cell renal cell carcinoma. Cell Div, 2023, 18(1): 21

[9] Á. Martínez-Barriocanal, D. Arango, H. Dopeso. PVT1 Long Non-coding RNA in Gastrointestinal Cancer. Front Oncol, 2020, 10: 38

[10] M. R. Jensen, U. Stoltze, T. V. O. Hansen, M. Bak, A. Sehested, C. Rechnitzer, et al. 9p21.3 Microdeletion involving CDKN2A/2B in a young patient with multiple primary cancers and review of the literature. Cold Spring Harb Mol Case Stud, 2022, 8(4): 6

[11] J. Z. Wang, V. Patil, J. Liu, H. Dogan, G. Tabatabai, L. S. Yefet, et al. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol, 2023, 146(1): 145-162

[12] T. S. Worst, C. A. Weis, R. Stöhr, S. Bertz, M. Eckstein, W. Otto, et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep, 2018, 8(1): 14383

[13] A. Nash, T. Firth Née Phan, J. Creaney. New Markers for Management of Mesothelioma. Semin Respir Crit Care Med, 2023, 44(4): 491-501